DoH Policies screened during the period: 1 October 2022- 31 December 2022
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Technology Appraisal TA824 - Dexamethasone intravitreal implant for treating diabetic macular oedema (partial review of TA349) (PDF 513KB)
- NICE Clinical Guideline NG222 - Depression in adults: treatment and management (updates and replaces CG90) (PDF 557KB)
- NICE Technology Appraisal TA823 - Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (PDF 512KB)
- NICE Technology Appraisal TA825 - Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (PDF 511KB)
- NICE Clinical Guideline NG224 - Urinary tract infection in under 16s: diagnosis and management (updates and replaces CG54) (PDF 517KB)
- NICE Technology Appraisal TA799 - Faricimab for treating diabetic macular oedema (PDF 511KB)
- Future of Muckamore Abbey Hospital (MAH) (PDF 615KB)
- NICE Technology Appraisal TA829 - Upadacitinib for treating active ankylosing spondylitis (PDF 512KB)
- NICE Technology Appraisal TA828 - Ozanimod for treating moderately to severely active ulcerative colitis (PDF 513KB)
- NICE Technology Appraisal TA827 - Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (PDF 513KB)
- NICE Technology Appraisal TA831 - Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (PDF 512KB)
- NICE Technology Appraisal TA830 - Pembrolizumab for adjuvant treatment of renal cell carcinoma (PDF 512KB)
- NICE Technology Appraisal TA832 - Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (PDF 512KB)
- NICE Technology Appraisal TA837 - Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (PDF 512KB)
- NICE Technology Appraisal TA816 - Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (PDF 513KB)
- NICE Technology Appraisal TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (PDF 515KB)
- Delivery of a SARS CoV-2 Wastewater Surveillance Programme – Northern Ireland (September 2021 – March 2023)
- NICE Technology Appraisal TA787 - Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable